How were Aquinox Pharmaceuticals' earnings last quarter?

Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) issued its quarterly earnings data on Thursday, November, 8th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by $0.43.

What other stocks do shareholders of Aquinox Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aquinox Pharmaceuticals investors own include Novavax (NVAX) , Bausch Health Companies (BHC) , Sarepta Therapeutics (SRPT) , ACADIA Pharmaceuticals (ACAD) , Gilead Sciences (GILD) , XOMA (XOMA) , Alnylam Pharmaceuticals (ALNY) , Inovio Pharmaceuticals (INO) , SodaStream International (SODA) and ZIOPHARM Oncology (ZIOP) .

NASDAQ:AQXP

Aquinox Pharmaceuticals (AQXP) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free AQXP Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $30.85
▼
$33.81
50-Day Range: $3.68
▼
$4.03
52-Week Range: $2.00
▼
$3.84

Volume: 100,284 shs
Average Volume: 239,362 shs
Market Capitalization: $743.39 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Competitors Social Media

Get Aquinox Pharmaceuticals alerts:

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Aquinox Pharmaceuticals Stock (NASDAQ:AQXP)

Aquinox Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in developing novel therapeutics for chronic urological conditions by inflammation and pain. The company focuses on a library of novel compounds that activate SH2-containing inositol-5'-phosphatase 1 (SHIP1) to develop therapeutics for application in inflammation, inflammatory pain, and blood cancers. Its lead product candidate is Rosiptor (Leadership 301), a small molecule activator of SHIP1 that is in Phase III clinical trials for treatment in interstitial cystitis/bladder pain syndrome. The company was formerly known as Aquinox Pharmaceuticals (USA) Inc. and changed its name to Aquinox Pharmaceuticals, Inc. in January 2014. Aquinox Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Vancouver, Canada.

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

AQXP Stock News Headlines

February 11, 2024 | finance.yahoo.com

Mirum Pharmaceuticals, Inc. (MIRM)

September 24, 2023 | finance.yahoo.com

Why Aquinox Pharma (AQXP) Stock Might be a Great Pick

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

July 26, 2023 | thestreet.com

Aquinox Pharmaceuticals (AQXP) Stock Jumping in After-Hours Trading Following Earnings Beat

June 9, 2022 | seekingalpha.com

Aquinox Pharma's lead product candidate flunks mid-stage trial in COPD; shares plummet 70%

See More Headlines

Receive AQXP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aquinox Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/08/2018
Today: 4/19/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical Preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:AQXP
CUSIP: N/A
CIK: 1404644
Web: www.aqxpharma.com
Phone: 604-629-9223
Fax: N/A
Employees: 8
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-31,580,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -30.13%
Return on Assets: -28.08%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 63.17
Quick Ratio: 63.17

Sales & Book Value

Annual Sales: $25 million
Price / Sales: 31.68
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.09 per share
Price / Book: 10.89

Miscellaneous

Outstanding Shares: 23,540,000
Free Float: N/A
Market Cap: $791.89 million
Optionable: Not Optionable
Beta: -7.37

The 10 Best AI Stocks to Own in 2024

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

Mr. David J. Main (Age 54)
Co-Founder, Chairman, CEO & Pres
Mr. Kamran Alam (Age 45)
CFO, VP of Fin. & Corp. Sec.
Ms. Shelley McCloskey (Age 59)
VP of HR & Admin.

Key Competitors

View All Competitors

AQXP Stock Analysis - Frequently Asked Questions

How were Aquinox Pharmaceuticals' earnings last quarter?: Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) issued its quarterly earnings data on Thursday, November, 8th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by $0.43.
What other stocks do shareholders of Aquinox Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Aquinox Pharmaceuticals investors own include Novavax (NVAX), Bausch Health Companies (BHC), Sarepta Therapeutics (SRPT), ACADIA Pharmaceuticals (ACAD), Gilead Sciences (GILD), XOMA (XOMA), Alnylam Pharmaceuticals (ALNY), Inovio Pharmaceuticals (INO), SodaStream International (SODA) and ZIOPHARM Oncology (ZIOP).

This page (NASDAQ:AQXP) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Aquinox Pharmaceuticals (AQXP) Stock Price, News & Analysis

About Aquinox Pharmaceuticals Stock (NASDAQ:AQXP)

AQXP Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

AQXP Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info